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Abstract: During surgery or infection, peripheral inflammation can lead to neuroinflammation,
which is associated with cognitive impairment, neurodegeneration, and several neurodegenerative
diseases. Dexmedetomidine, an α-2-adrenoceptor agonist, is known to exert anti-inflammatory
and neuroprotective properties and reduces the incidence of postoperative cognitive impairments.
However, on the whole the molecular mechanisms are poorly understood. This study aims to explore
whether dexmedetomidine influences microRNAs (miRNAs) in a rat model of lipopolysaccharide
(LPS)-induced neuroinflammation. Adult Wistar rats were injected with 1 mg/kg LPS intraperitoneal
(i.p.) in the presence or absence of 5 µg/kg dexmedetomidine. After 6 h, 24 h, and 7 days, gene
expressions of interleukin 1-β (IL1-β), tumor necrosis factor-α (TNF-α), and microRNA expressions of
miR 124, 132, 134, and 155 were measured in the hippocampus, cortex, and plasma. Dexmedetomidine
decreased the LPS-induced neuroinflammation in the hippocampus and cortex via significant
reduction of the IL1-β and TNF-α gene expressions after 24 h. Moreover, the LPS-mediated increased
expressions of miR 124, 132, 134, and 155 were significantly decreased after dexmedetomidine
treatment in both brain regions. In plasma, dexmedetomidine significantly reduced LPS-induced
miR 155 after 6 h. Furthermore, there is evidence that miR 132 and 134 may be suitable as potential
biomarkers for the detection of neuroinflammation.
Keywords: neuroinflammation; dexmedetomidine; miRNA; hippocampus; cortex
1. Introduction
Neuroinflammation plays a major role in the pathogenesis of several neurodegenerative diseases.
A clinical and experimental correlation between elevated peripheral proinflammatory cytokines and
neuroinflammation has been largely described [1–3]. Lipopolysaccharide (LPS) or surgical trauma
activate the immune system and are capable of causing memory impairment [3–5]. Studies indicate
that high levels of the proinflammatory cytokines interleukin 1-β (IL1-β) and tumor necrosis factor-α
(TNF-α) are associated with postoperative cognitive impairments [6,7]. These are characterized
by neuronal dysfunction and/or neuronal death, which can induce long-lasting cognitive decline
and aggravation in learning and memory [2,3,8]. Surgery, especially in the elderly, can lead to
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neuroinflammation, cause long-lasting postoperative cognitive impairments, and permanently affect
the patient’s life [9,10]. Patients with those impairments have a higher risk of developing postoperative
complications such as sepsis, and show a higher mortality rate [11,12].
Dexmedetomidine, a highly selective α-2-adrenergic agonist, exerts sedative, anxiolytic, and
analgesic properties and is therefore used as perioperative sedative agent [13]. Several studies indicate
that dexmedetomidine has protective properties regarding postoperative cognitive impairments in
clinical trials [14–17]. Compared to other anesthetics, dexmedetomidine shortens the duration of artificial
ventilation, the extubating time, and the occurrence of postoperative cognitive impairments [18–21].
Dexmedetomidine shows anti-inflammatory as well as neuroprotective properties in several cell and
rodent studies [8,22–29]. In different rodent behavior experiments, dexmedetomidine also prevents the
occurrence of cognitive impairments [30,31]. However, the exact molecular mechanisms of the positive
and protective character of dexmedetomidine are not entirely understood.
MicroRNAs (miRNAs) are approximately 22 base pairs long, non-coding RNAs which play
a significant role in post-transcriptional gene regulation. It is currently assumed that about 60% of
all genes are regulated by miRNAs [32]. The majority of known miRNAs are found in the brain,
whereas some of them are exclusive to neuronal tissue [33,34]. Depending on the complementarity
of the binding between miRNA and mRNA, the mRNA is degraded or its translation repressed [35].
Studies have shown that the expression of certain miRNAs is altered in different neurodegenerative
processes [36].
The aim of this study was to determine whether dexmedetomidine has an impact on the expression
of IL1-β, TNF-α, and several miRNAs in the hippocampus and cortex in a neuroinflammation model of
adult rats. Additionally, miRNAs that showed an altered expression in the brain were measured also
in plasma to study whether dexmedetomidine influences LPS-induced changes and whether those
miRNAs may be suitable biomarkers for the detection of neuroinflammation.
2. Results
2.1. Dexmedetomidine-Attenuated, LPS-Induced IL1-β and TNF-α Gene Expression in the Hippocampus
and Cortex
As shown in Figure 1, the administration of 1 mg/kg LPS caused a significant upregulation of
IL1-β (Figure 1A,B) and TNF-α (Figure 1C,D) gene expression after 6 and 24 h in the hippocampus
and cortex compared to the saline-treated rats. Seven days post LPS injection, the IL1-β expression
was still significantly elevated in the cortex compared to the control. Dexmedetomidine significantly
reduced the LPS-induced rise of both cytokines after 24 h, indicating an anti-inflammatory effect of
this drug. Despite the dexmedetomidine-mediated reduction of LPS-induced IL1-β expression in
the hippocampus, the expression was significantly elevated compared to the saline-treated animals.
Twenty-four hours after LPS injection, the dexmedetomidine-treated animals showed TNF-α levels
similar to the control group in both brain regions. Seven days after LPS injection dexmedetomidine
was still able to reduce the LPS-mediated rise of IL1-β in the cortex. The drug alone significantly
decreased hippocampal IL1-β expression after 7 days.
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Figure 1. Representation of interleukin 1-β (IL1-β) (A,B) and tumor necrosis factor-α (TNF-α) (C,D) 
gene expression after LPS (lipopolysaccharide) and dexmedetomidine treatment. Results are shown 
as mean ± standard error of the mean (SEM) (n  =  6–8 per group). Data are normalized to levels of 
saline-treated rats (control  =  100%). * p < 0.05, ** p < 0.01, and *** p < 0.001 represent the difference 
compared to saline-treated groups. # p < 0.05, ## p < 0.01, and ### p < 0.001 represent the difference 
between LPS and LPS in combination with dexmedetomidine-treated groups. 
2.2. Dexmedetomidine Modulated the miRNA Expression in the Hippocampus, Cortex, and Plasma of LPS 
Treated Rats 
The aim of this study was to determine whether dexmedetomidine influences the expression of 
different miRNAs in the brain and the plasma of adult rats in a neuroinflammation model. 
2.2.1. Expression of MicroRNA 124 
As shown in Figure 2, the administration of LPS mediated a significant increase of miR 124 
expression after 24 h in the hippocampus (Figure 2A) and the cortex (Figure 2B) compared to the 
respective control groups. LPS-induced expression of miR 124 was more pronounced in the cortex 
than in the hippocampus. After 7 days the endotoxin had no influence on the expression of this 
miRNA. LPS in combination with dexmedetomidine prevented LPS-induced miR 124 expression 
after 24 h in both investigated brain regions significantly. Six hours after LPS and dexmedetomidine 
administration miR 124 was significantly enhanced in the cortex, whereas it was significantly reduced 
after 7 days compared to the respective control. Moreover, the drug alone caused a significant, 
enhanced miR 124 expression after 6 h in the cortex when compared to the control. In plasma, miR 
124 expression was not detectable at any time point. 
Figure 1. Representation of interleukin 1-β (IL1-β) (A,B) and tumor necrosis factor-α (TNF-α) (C,D)
gene expression after LPS (lipopolysaccharide) and dexme eto idine treatment. Results are shown
as mean ± sta dard error of the mean (SEM) (n = 6–8 per gr up). Data are normalized to levels of
salin -treated rats (control = 100%). * p < 0.05, ** p < 0.01, and *** p < 0.001 represent the difference
compar d to s line-treated groups. # . , ## . , ### .001 r r se t t e iff r ce
between LPS and LPS in combination with dexmedetomidine-treated groups.
2.2. Dexmedetomidine Modulated the miRNA Expression in the Hippocampus, Cortex, and Plasma of LPS
Treated Rats
The aim of this study was to determine whether dexmedetomidine influences the expression of
different miRNAs in the brain and th plasma of adult rats in a neuroinflammation model.
2.2.1. Expression of MicroRNA 124
As shown in Figure 2, the administration of LPS mediated a significant increase of miR 124
expression after 24 h in the hippocampus (Figure 2A) and th cortex (Figure 2B) compared to the
resp ctive control groups. LPS-induced expression of miR 124 was more pronounced in the cortex than
in the hipp campus. After 7 days the endotoxin had no influence on th expression of this miRNA.
LPS in combination with dexmedetomidine prevented LPS-i duced miR 124 expr ssion after 24 h in
both investigated brain regi s significantly. Six hours after LPS and dexmedetomidine administratio
miR 124 was significantly enhanced in the cortex, whereas it was significantly re uced after 7 ays
co pared o the respective control. Moreover, the drug alone caused a significant, enhanced miR 124
exp ession after 6 h in the cortex when compared to the control. In plasma, miR 124 expression was
not det ctable at any time point.
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Figure 2. Representation of miR 124 expression after LPS and dexmedetomidine treatment in the 
hippocampus (A) and cortex (B). Results are shown as mean ± SEM (n  =  6–8 per group). Data are 
normalized to levels of saline-treated rats (control  =  100%). * p < 0.05, ** p < 0.01, and *** p < 0.001 
represent the difference compared to saline-treated groups. # p < 0.05 and ### p < 0.001 represent the 
difference between LPS and LPS in combination with dexmedetomidine-treated groups. 
2.2.2. Expression of MicroRNA 132 
Rats treated with LPS showed a significant upregulation of miR 132 expression in the 
hippocampus after 6 and 24 h when compared to the control, whereas the endotoxin had no influence 
on the expression after 7 days (Figure 3A). Dexmedetomidine in combination with LPS significantly 
prevented the LPS-mediated upregulation of miR 132 in this brain region after 24 h. The drug alone 
caused a significant rise of miR 132 expression after 6 h in the hippocampus that is comparable with 
the LPS-induced expression. 
In the cortex, treatment with LPS significantly enhanced the expression of miR 132 after 24 h, 
which was significantly reduced by administration of dexmedetomidine (Figure 3B). The drug alone 
rose miR 132 in the cortex after 24 h and 7 days in a significant way when compared to saline-treated 
rats. 
The miR 132 expression in plasma significantly increased 24 h and 7 days post LPS 
administration, what was not influenced by dexmedetomidine (Figure 3C). After 6 h, the combination 
of dexmedetomidine and LPS significantly reduced the miR 132 expression in plasma compared to 
the control and the LPS group. The drug alone reduced plasma miR 132 after 24 h and 7 days 
significantly. 
 
Figure 3. Representation of miR 132 expression after LPS and dexmedetomidine treatment in the 
hippocampus (A), cortex (B), and plasma (C). Results are shown as mean ± SEM (n  =  6–8 per group). 
Data are normalized to levels of saline-treated rats (control  =  100%). * p < 0.05, ** p < 0.01, and *** p < 
0.001 represent the difference compared to saline-treated groups. # p < 0.05 and ## p < 0.01 represent 
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Figure 2. Representation of miR 124 expression after LPS and dexmedetomidine treatment in the
hippocampus (A) and cortex (B). Results are shown as mean ± SEM (n = 6–8 per group). Data are
normalized to levels of saline-treated rats (control = 100%). * p < 0.05, ** p < 0.01, and *** p < 0.001
represent the difference compared to saline-treated groups. # p < 0.05 and ### p < 0.001 represent the
difference between LPS and LPS in combination with dexmedetomidine-treated groups.
2.2.2. Expression of MicroRNA 132
Rats treated with LPS showed a significant upregulation of miR 132 expression in the hippocampus
after 6 and 24 h when compared to the control, whereas the endotoxin had no influence on the
expression after 7 days (Figure 3A). Dexmedetomidine in combination with LPS significantly prevented
the LPS-mediated upregulation of miR 132 in this brain region after 24 h. The drug alone caused
a significant rise of miR 132 expression after 6 h in the hippocampus that is comparable with the
LPS-induced expression.
In the cortex, treatment with LPS significantly enhanced the expression of miR 132 after 24 h, which
was significantly reduced by administration of dexmedetomidine (Figure 3B). The drug alone rose
miR 132 in the cortex after 24 h and 7 days in a significant way when compared to saline-treated rats.
The miR 132 expression in plasma significantly increased 24 h and 7 days post LPS administration,
what was not influenced by dexmedetomidine (Figure 3C). After 6 h, the combination of
dexmedetomidine and LPS significantly reduced the miR 132 expression in plasma compared to the
control and the LPS group. The drug alone reduced plasma miR 132 after 24 h and 7 days significantly.
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Figure 3. Representation of miR 132 expression after LPS and dexmedetomidine treatment in the
hippocampus (A), cortex (B), and plasma (C). Results are shown as mean ± SEM (n = 6–8 per group).
Data are normalized to levels of saline-treated rats (control = 100%). * p < 0.05, ** p < 0.01, and
*** p < 0.001 represent the difference compared to saline-treated groups. # p < 0.05 and ## p < 0.01
represent the difference between LPS and LPS in combination with dexmedetomidine-treated groups.
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2.2.3. Expression of MicroRNA 134
In comparison to saline-treated rats, expression of miR 134 was significantly upregulated 6 and
24 h after LPS treatment in the hippocampus of adult rats (Figure 4A). Dexmedetomidine significantly
attenuated LPS-induced miR 134 expression in this brain region. The drug alone caused a significant
increase of miR 134 after 6 h in the hippocampus compared to control.
In the cortex, treatment with LPS also significantly increased miR 132 expression after 6 and
24 h (Figure 4B) compared to the control, what was significantly reduced by the administration of
dexmedetomidine after 24 h.
In comparison to brain tissue, plasma miR 134 significantly decreased at all time points in
LPS-treated animals (Figure 4C). Dexmedetomidine alone and in combination with LPS significantly
reduced the expression of miR 134 after 6 h compared to saline-treated rats. The combination of
dexmedetomidine and LPS enhanced the expression of miR 134 after 7 days significantly compared to
the LPS group.
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influence on the expression after 6 h and 7 days. The drug alone led to a significant increase of miR 
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When compared to respective control groups, miR 155 was significantly enhanced in the cortex 
6 and 24 h following LPS exposition (Figure 5B). Dexmedetomidine significantly inhibited the LPS-
induced expression after 24 h but compared to control group the expression was still significantly 
increased. LPS, in combination with dexmedetomidine, significantly elevated miR 155 after 7 days in 
the cortex compared to the control. 
In the plasma, LPS mediated a significant enhancement of miR 155 after 6 and 24 h and a 
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even significantly downregulated compared to the saline-treated animals. Moreover, the drug alone 
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Figure 4. Representation of miR 134 expression after LPS and dexmedetomidine treatment in the
hippocampus (A), cortex (B), and plasma (C). Results are shown as mean ± SEM (n = 6–8 per group).
Data are normalized to levels of saline-treated rats (control = 100%). * p < 0.05 and ** p < 0.01 represent
the difference compared to saline-treated groups. # p < 0.05 and ## p < 0.01 represent the difference
between LPS and LPS in combination with dexmedetomidine-treated groups.
2.2.4. Expression of icroRNA 155
LPS significantly increased the expression of miR 155 at all investigated time points in the
hippocampus (Figure 5A) compared to the saline-treated rats. Application of dexmedetomidine
significantly reduced LPS-mediated, enhanced miR 155 expression after 24 h, whereas it had no
influence on the expression after 6 h and 7 days. The drug alone led to a significant increase of miR 155
after 6 h in the hippocampus that is comparable with the LPS-induced expression of this miRNA.
hen co pared to respective control groups, iR 155 was significantly enhanced in the cortex
6 and 24 h following LPS exposition (Figure 5B). Dexmedetomidine significantly inhibited the
LPS-induced expression after 24 h but compared to control group the expression was still significantly
increased. LPS, in combination with dexmedetomidine, significantly elevated miR 155 after 7 days in
the cortex co pared to the control.
In the plasma, LPS mediated a significant enhancement of miR 155 after 6 and 24 h and a significant
reduction after 7 days (Figure 5C). Dexmedetomidine, in combination with LPS, significantly decreased
the LPS-induced miR 155 level after 6 h in the plasma in a way that it was even significantly
downregulated compared to the saline-treated animals. Moreover, the drug alone caused a decrease of
miR 155 at all time points in the plas a when compared to the control animals.
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Figure 5. Representation of miR 155 after LPS and dexmedetomidine treatment in the hippocampus (A),
cortex (B), and plasma (C). Results are shown as mean± SEM (n = 6–8 per group). Data are normalized
to levels of saline-treated rats (control = 100%). * p < 0.05, ** p < 0.01, and *** p < 0.001 represent the
difference compared to saline-treated groups. # p < 0.05 and ### p < 0.001 represent the difference
between LPS and LPS in combination with dexmedetomidine-treated groups.
3. Discussion
The aim of this study was to investigate the effect of dexmedetomidine on LPS-induced
neuroinflammation, and miRNA expression in the hippocampus and cortex of the adult rat brain, as
those brain regions play a major role in cognition and memory. Our study demonstrates that treatment
with dexmedetomidine reduced LPS-mediated neuroinflammation and prevented LPS-induced
enhancement of miR 124, 132, 134, and 155.
Many studies have already shown in rodents that systemic administration of LPS activates
the innate immune system, which leads to neuroinflammation, memory impairment, and neuronal
cell death, particularly in the cortical and hippocampal regions of the rodent brain [1–4]. High
concentrations of IL1-β and TNF-α in the brain are associated with cognitive impairments [5–7].
Dexmedetomidine, a selective α-2-agonist, reduces the occurrence of cognitive impairments in animal
and human studies, but the molecular mechanisms are not entirely understood. In the work at
hand, dexmedetomidine was applied shortly before LPS treatment. The drug is known to exert
protective properties when applied before intervention in several animal studies [23,30,31]. A study
from Yamanaka showed that only early dexmedetomidine (applied directly after intervention), but
not late dexmedetomidine (applied 24 h after intervention), exerts protective effects [31]. Some
studies also show protective properties after drug treatment 30 min post-damage induction [37,38].
Nevertheless, we chose a dexmedetomidine treatment prior to LPS application to reduce potential
LPS-induced damage as fast as possible. Dexmedetomidine treatment decreased LPS-induced IL1-β
and TNF-α mRNA expression in the hippocampus and cortex after 24 h in our model. At this point, the
TNF-α concentration returned to control levels, whereas IL1-β was still elevated in both brain regions
when compared to the control. Via reducing LPS-induced IL1-β expression after 7 days in the cortex,
dexmedeto idine seems to have long-lasting anti-inflammatory properties. Ning et al. previously
published that dexmedetomidine reduced IL1-β, TNF-α, and oxidative stress in mice brain after
systemic LPS administration [8]. In the lungs of septic rats, dexmedetomidine inhibits inflammation
via the toll like receptor 4/myeloid differentiation factor 88/ nuclear factor kappa-light-chain-enhancer
of activated B cells (TLR4/MyD88/NF-κB) signaling pathway [39]. Moreover, an involvement of the
cholinergic anti-inflammatory pathway is described in dexmedetomidine´s anti-inflam atory action
in different rodent studies [22,23,40].
iRNAs regulate about 60% of genes on the posttranscriptional level and play an important role in
different cell processes [32]. In our work, we investigated four miRNAs that are believed to play a role
in inflammation and cognition: miR 124, 132, 134, and 155. A study from 2013 proposed members of the
miR-132 and miR-134 families as biomarkers for the detection of mild cognitive impairment (MCI) [41].
As the anti-inflammatory cholinergic system plays an important role in the inflammation response,
we investigated miR-124 and 132, because these miRNAs are known to influence this pathway [42].
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Moreover, serum expression of miRNA-155 was shown by multiple logistic regression analysis to be
an independent predictive indicator for postoperative cognitive impairment after surgery [43].
LPS administration increased the expression of all investigated miRNAs at several time points
significantly in the hippocampus and cortex of adult rats. The measured miRNA level was higher in the
cortex than in the hippocampus, indicating a stronger involvement of the cortex in the LPS-mediated
miRNA machinery. After 7 days miR 124, 132, and 134 expressions were restored to a normal level,
whereas miR 155 was still significantly upregulated in the hippocampus. Expression of miR 155 is
known to be high in the central nervous system (CNS) of amyotrophic lateral sclerosis (ALS) and
multiple sclerosis (MS) patients, two inflammation-related disorders [44]. High expressions of miR 155
could be a potential trigger for long lasting CNS changes in our model after administration of 1 mg/kg
LPS, but this hypothesis needs further research. Even if 6 h following LPS administration some
miRNAs were slightly elevated in the brain, we suggest that the high cytokine expressions after 6 h are
inducing the miRNAs after 24 h. It is described that cytokines induce individual miRNAs. A study
from Liu et al. indicates that in LPS-stimulated alveolar macrophages, miR 132 is upregulated after
measurement of high concentrations of IL1-β and TNF-α [45]. In a human monocyte cell line, miR 132
and 155 are upregulated after IL1-β or TNF-α exposure [46]. Moreover, murine macrophages exposed
to TNF-α show an increased miR 155 expression [47]. We suspect that the level of proinflammatory
cytokines is crucial for the activation of miRNAs in our model. Induction of miRNAs after LPS
treatment can be explained as a potential counter reaction and/or protection against LPS-induced
damage to participate in attenuating inflammation via indirect suppression of cytokines.
miR 124 is the most abundant miRNA expressed in the CNS and is an essential factor for neuronal
differentiation. It is described as “neurimmiR”, indicating an involvement in the nervous and immune
systems [42]. In our model, LPS treatment significantly increased miR 124 expression after 24 h in
the hippocampus and the cortex. An upregulation of miR 124 could also be detected in LPS-treated
mouse macrophages and mice, where it was reported to be a critical mediator of the cholinergic
anti-inflammatory action [48,49].
miR 132, that is, enhanced after LPS treatment in our model in the hippocampus and the cortex,
also acts as “neurimmiR” [42]. This miRNA is induced in primary human macrophages, rat alveolar
macrophages, and several organs of mice after LPS treatment [45,50]. miR 132 functions as a negative
regulator of the inflammatory response in alveolar macrophages by potentiating the cholinergic
anti-inflammatory pathway [45]. Acetylcholinesterase, an enzyme that cleaves acetylcholine in choline
and acetic acid, is a validated target of miR 132 [45,50,51]. Inhibition of this esterase leads to higher
acetylcholine amounts, which can mediate anti-inflammatory properties via binding on α-7-nAChR
on macrophages. Moderate overexpression of miR 132 was shown to improve cognition, whereas
high overexpression of this miRNA in rat cortex and mouse forebrain is associated with cognitive
impairments [52–54]. Moreover, miR 132 knockout animals exert deficits in memory [55]. Therefore,
miR 132 expression needs to be precisely controlled in brain tissue.
miR 134 was significantly upregulated after LPS treatment in the hippocampus and the cortex in
our model. This brain-specific miRNA is activity-regulated and associated with the control of dendritic
spine morphology. Elevated miR 134 levels are linked to impaired synaptic plasticity [56,57], whereas
overexpression of this miRNA is associated with a reduced spine volume and reduced synaptic
strength. Gao et al. proved that high miR 134 expressions result in impaired long-term potentiation in
the hippocampus [57].
In our study, LPS elevates the expression of miR 155 in the hippocampus the and cortex, which is in
agreement with other reports. miR 155 is one of the best-described miRNAs concerning inflammation.
This miRNA is described to participate in pro- and anti-inflammatory mechanisms. Quinn et al.
published that LPS-induced expression of transcription factor E26 transformation-specific 2 (Ets2) is
responsible for induction of miR 155 expression, but also the NF-κB and mitogen-activated protein
kinase (MAPK) pathway, which is activated during LPS infection, stimulates the expression of
miR 155 [58]. miR 155 can bind to several modulators of toll like receptor (TLR)/IL-1 signaling
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to attenuate expression of cytokines in mouse monocyte-derived dendritic cells, macrophages,
and mice [59,60]. Via targeting phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1 (SHIP1),
a negative regulator of TNF-α, and suppressor of cytokine signaling 1 (SOCS1), a negative regulator
of cytokines, miR 155 also mediates an increased inflammatory response. Treating mice with LPS
decreases neurogenesis in the hippocampus, which might be a consequence of miR 155-mediated IL-6
production in microglia [44].
The investigated miRNAs were not just only measured in brain, but also in plasma in our study.
Because of their good stability and tissue specificity, these small non-coding RNAs are suitable as
circulating biomarkers. The usage of miRNAs as biomarkers has several advantages compared
to other biomarkers: miRNAs are stably expressed in plasma and even low expressions can be
detected by qPCR (semiquantitative Real Time PCR) [61]. Moreover, miRNAs do not have any
posttranslational modifications, which can influence their measurement [61]. Identifying miRNAs as
suitable biomarkers for the fast and reliable detection of neuroinflammation is important, for instance,
for the fast recognition of postoperative cognitive impairments after surgery, since rapid recognition
and initiation of a proper countermeasure is essential to improving the outcome of patients. In our
study, plasma miR 132 increased significantly 24 h and 7 days after LPS stimulation. A study from
2015 suggests miR 132 as a circulating biomarker for the detection of MCI, a cognitive decline that is
associated with a high risk of developing Alzheimer Dementia [62]. Our study supports that miR 132
might be a potential marker for the detection of neuroinflammation, because it is enhanced in plasma
after massive upregulation in the brain, indicating a release of miR 132 from the brain into the plasma.
To prove if miR 132 is a suitable target for the detection of neuroinflammation in plasma, further
research will be necessary. Expression of miR 134 was significantly reduced at all time points after
LPS treatment in our study. Avansini et al. recently published that miR 134 is downregulated in the
plasma of patients with mesial temporal lobe epilepsy, whereas it is upregulated in the hippocampus
of the patients [63]. Therefore, miR 134 might be a potential circulating biomarker for the detection
of functional changes in the brain. Because of its downregulation after 6 h, 24 h, and 7 days, miR
134 may be used as an early and late marker of neuroinflammation. This point needs to be further
investigated and validated. LPS-induced enhancement of miR 155 expression in plasma in the study at
hand is, in our opinion, more a consequence of peripheral inflammation rather than an indicator of
neuroinflammation, as miR 155 is unspecific and upregulated during inflammation.
To our knowledge, this study explores for the first time that dexmedetomidine significantly
suppressed the expression of miR 124, 132, 134, and 155 after LPS-induced neuroinflammation in
the hippocampus and cortex. Dexmedetomidine mediated suppression of the cytokines IL1-β and
TNF-α may prevent massive upregulation of all investigated miRNAs, because of the lower level
of inflammation, for which there is no trigger for miRNA induction. Application of the drug alone
does not cause any effects, as there is no trigger to counteract any intervention. Via suppressing the
LPS-induced TLR4/MyD88/NF-κB and MAPK pathway, dexmedetomidine may avert upregulation of
miR 155, as NF-κB and MAPK are known stimulators of this miRNA [58]. Whether dexmedetomidine’s
attenuation of miRNA expression is directly regulated in the brain or a consequence of reduced
peripheral inflammation cannot be determined. This point must be further investigated, but we
hypothesize that dexmedetomidine-induced anti-inflammatory peripheral actions probably reduce
vagus nerve signaling to the brain, which results in reduced neuroinflammation and therefore reduced
miRNA expression. Ning et al. published that LPS-induced disturbance of the blood-brain barrier
can be attenuated by dexmedetomidine [8]. We speculate that this might be a consequence of the
dexmedetomidine-mediated reduction of miR 155, as miR 155 is described as a negative regulator of
the blood-brain barrier during neuroinflammation. As the drug partly triggers the same pathways
like LPS-induced miRNAs in our model, dexmedetomidine in parts mimics the endogen miRNA
function to attenuate inflammation without negative side effects. Because high amounts of miR 132
and 134 are known to participate in impaired memory function and impaired synaptic plasticity,
we speculate that dexmedetomidine-mediated preventive enhancement of those miRNAs can be
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a potential reason for the better outcome of animals and patients profiting from dexmedetomidine in
different cognition studies.
Dexmedetomidine is more likely to influence the miRNA expression in the brain than in plasma
after LPS administration. In plasma, the drug downregulated miR 132, 134, and 155, in combination
with LPS after 6 h compared to the control and LPS-treated groups, whereas miR 155 was the only
LPS-induced miRNA in plasma. Reduction of miR 155 after 6 h can be interpreted as a sign of
reduced peripheral inflammation. After 24 h and 7 days, dexmedetomidine had no influence on the
LPS-induced miR 132 and 155 expressions in plasma. miR 132 and 134 are both significantly enhanced
7 days after dexmedetomidine administration in combination with LPS, indicating long-lasting miRNA
changes in plasma after endotoxin in combination with drug administration.
There are several limitations in our study. First, we only measured cytokine expressions on
an mRNA level, to prove our model. Second, no behavior tests were performed, so we do not
know whether high concentrations of miR 132 and 134 in our model are associated with cognitive
impairments and whether dexmedetomidine can reduce these. Further research is needed to clarify
how dexmedetomidine exactly influences the miRNA expression to get a full understanding of its
protective properties. Therefore, analyses with specific miRNA mimics and inhibitors should be
performed in cell culture experiments. Moreover, dexmedetomidine was applied only once before LPS
treatment, while in the clinical setting it is infused over a longer period. To prove the usage of miR 132
and 134 as potential biomarkers, a validation step is essential. This should be performed in the plasma
of patients suffering from neuroinflammation.
Taken together, our data indicate for the first time that dexmedetomidine does not just only
reduce LPS-mediated, enhanced cytokine expression, but also prevents LPS-induced expression
of miR 124, 123, 134, and 155 in the adult hippocampus and cortex during neuroinflammation.
That opens new approaches to understand the molecular mechanism of dexmedetomidine-mediated
protection. Moreover, there are hints that miR 132 and 134 may be suitable plasma biomarkers
for neuroinflammation.
4. Materials and Methods
4.1. Animal Model
Adult male Wistar rats (250–300 g) underwent intraperitoneal (i.p.) LPS injection in the presence
or absence of the α-2-receptor agonist dexmedetomidine (DEX). Rats were treated with i.p. LPS
(1 mg/kg body weight), i.p. DEX (dexdor®, Orion Pharma, Espoo, Finland; 5 µg/kg body weight),
or control vehicle NaCl (0.9%) after a short anesthesia in isoflurane-oxygen narcosis. Animals were
divided into four groups: (1) NaCl, (2) LPS, (3) DEX, and (4) LPS+DEX. DEX was administrated 10 min
before LPS treatment. Rats were hosted in groups at room temperature (22 ± 2 ◦C) under a standard
12–12 h light-dark cycle. Food and water were available ad libitum. All animal experiments were
approved and performed in accordance with the guidelines of the Charité-Universitätsmedizin Berlin,
Germany and the national ethic principles (registration no. G 0145/13, 1 July 2013).
4.2. Tissue Preparation
After 6 h, 24 h, 7 days, the animals were sacrificed in deep isoflurane-oxygen narcosis. The rats
were transcardially perfused with normal saline (pH 7.4) and then decapitated. The brain was
immediately removed and divided into two hemispheres. The whole cortical and hippocampal tissue
was microdissected with a stereo magnifying glass from one hemisphere and directly snap frozen
in liquid nitrogen. To obtain plasma, EDTA whole blood was centrifuged at 2500× g for 10 min.
Afterward, the plasma was centrifuged again at 1000× g for 15 min and stored at −80 ◦C.
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4.3. RNA Extraction and Semiquantitative Real Time PCR
Total RNA containing miRNA was isolated from snap frozen hippocampus and cortex by acidic
phenol/chloroform extraction (peqGOLD RNAPure; PEQLAB Biotechnologie, Erlangen, Germany)
according to the manufacturer’s instructions. RNAPure FL (PEQLAB) was used for the isolation of
miRNA from plasma. The RNA-precipitation from plasma was performed overnight using glycogen
as a carrier.
For the mRNA analyses, 2 µg of RNA underwent DNase treatment (Ambion, Austin, TX, USA)
and were reverse transcribed with 2 µM oligo d(T) 16 primer (Promega, Mannheim, Germany) and
200 U M-MLV reverse transcriptase (Promega) at 42 ◦C. The cDNA was quantified in real time with
dye-labeled probes and primers (metabion, Planegg/Steinkirchen, Germany) (sequences shown in
Table 1). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) functioned as the endogen control
gene. The concentration of cDNA used as input for semiquantitative Real Time PCR (qPCR) differed
from 50–100 ng. The qPCR volume was 13 µL, whereas 6.5 µL 2× mastermix (Applied Biosystems,
Foster City, CA, USA), 2.5 µL primer mix (1.25 µM) and 0.5 µL probe (0.5 µM).
miRNA analyses were performed after a method published by Balcells et al. [64]. Briefly, miRNA
is first polyadenylated and then reverse transcribed with a special primer (RT-primer). For qPCR
analyses, two specific primers for each miRNA were designed using a software tool from Busk [65].
For miRNA analysis from tissue, an amount of 500 ng, for plasma of 50 ng total RNA containing
miRNA, was reverse transcribed with 1 µM RT-primer (sequence shown in Table 1), 0.1 mM dNTP
mix, 1 mM ATP, 100 U M-MLV reverse transcriptase (Promega), 1 U Poly-A-Polymerase (New England
Biolabs, Frankfurt am Main, Germany), and 1 µL of 10× poly(A)polymerase buffer (New England
Biolabs). The volume was filled up to 10 µL and incubated for 60 min at 42 ◦C. 10 ng cDNA from tissue
and 1 ng cDNA from plasma were used as input for qPCR with 2× Bright Green (Promega, Mannheim,
Germany). SnU6RNA functioned as the endogen control for all miRNA analyses performed in brain
tissue. In plasma, miR 103 was used as reference miRNA. The mRNA and miRNA expressions were
analyzed with the ABI Prism® 7500 detection system (Applied Biosystems, Foster City, CA, USA) and
QuantStudio5® (Thermo Fisher, Darmstadt, Germany) according to the 2−∆∆CT method [66].
Table 1. Primer and probe sequences for messenger RNA (mRNA) and microRNA (miRNA) analyses.



















F gcagagcagcattgtacag miR 134
MIMAT0000840
F gcagtgtgactggttgac
R ggtccagtttttttttttttttcatag R cagtttttttttttttttcccctct
miR 124
MIMAT0004728
F gcagcgtgttcacagc miR 155
MIMAT0030409
F cgcagttaatgctaattgtgatag






R gtccagtttttttttttttttcgac R cgaatttgcgtgtcatccttg
4.4. Statistical Analyses
Experiments were performed in seven or eight animals per group (n = 7–8). Data were analyzed
using GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA). Values are presented as means ±
standard error of the mean (SEM). Comparisons among groups were made using the Mann-Whitney
U-test. p Values of <0.05 was considered to be significant.
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5. Conclusions
Dexmedetomidine attenuated LPS-induced neuroinflammation via reducing IL1-β and TNF-α
expression in the hippocampus and cortex of adult rats. Moreover, the drug prevented upregulation of
miR 124, 132, 134 and 155 after LPS application in both investigated brain regions.
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